Wild-type C9orf72 was linked to protein-clearance problems in experimental Huntington’s disease models
Original source
Wild-type C9orf72 drives proteasomal dysfunction and mutant aggregates via a Stat1-Isg15 axis in Huntington's disease. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse
Population inferred from the title and abstract by Compass.
Related topics
Researchers found that increased normal, or wild-type, C9orf72 promoted mutant Huntingtin aggregation in cells and in a mouse model of Huntington’s disease. They linked this effect to activation of Stat1 and increased Isg15, which impaired the ubiquitin-proteasome system. Blocking Stat1 or Isg15 reduced the aggregation in the experiments.
Why this matters
The findings point to a possible mechanism connecting C9orf72 with disrupted protein handling, but the work was conducted in Huntington’s disease models rather than people with amyotrophic lateral sclerosis (ALS) or frontotemporal dementia. It does not currently change treatment for ALS or Huntington’s disease.
Limitations and context
This was primary research using cell-based experiments, transcriptomic analyses and the R6/2 mouse model. The study tested a mechanism in experimental Huntington’s disease and did not establish that the same pathway drives disease in people with ALS, Huntington’s disease or frontotemporal dementia. No treatment benefit was demonstrated.